AbbVie (ABBV)
(Delayed Data from NYSE)
$196.30 USD
-2.25 (-1.13%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $196.54 +0.24 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABBV 196.30 -2.25(-1.13%)
Will ABBV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABBV
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
Economy Heating Up on PCE for June
Other News for ABBV
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
Evolus plunges after Q2 miss, guidance cut; Needham downgrades
Trump ups pharma tariff threat to 250%